As far SPN-830 and as we — when we announced the CRL, we did mention there are a couple of areas one around the quality and one around the master file, which we are learning more and more now as we’re having discussions directly with the manufacturer around that. We think these are areas that can be addressed and we already secured a meeting with the FDA later this month. So we’re really moving pretty fast, as fast as we can to hopefully address all these issues and wanting to make sure it also there are no new issues pop up later on. So, we’re trying to make sure we have everything we need before resubmission and that’s why we would like to have that meeting first before we communicate any time line for the resubmission. And then the last question on 817, just as a reminder the current study we are reporting on which was intended to interim data is on an open label exploratory study where we looked at several types of single-dose.
We looked at so many different doses and it was meant to help us, learn as time goes on as the study continues to enroll, help us in designing the Phase 2b study, which typically would be our next step. So clearly that is the next natural step after the Phase 2a open-label study and we will share the details with you guys on May 23.
Unidentified Analyst: And if I may just sneak in a follow-up on 830. There was also the — the other issue raised was on product quality. And I believe you said that you submitted that that data to the FDA. Is it possible to elaborate on what was meant by product quality?
Jack Khattar: Yes. I mean I don’t want to get into all the details at all. It’s regarding the formulation itself. So it’s not a device issue. So that’s when we say product quality. It was more related to the product, the formulation, the Apomorphine solution so to speak. That’s as far as we can share at this point. And yes, we have submitted some data at that time that the FDA didn’t have the time to review or didn’t review. So clearly the meeting upcoming hearing will be very important for us to clarify do they need anything else on top of that or whatever we submitted could be sufficient. So that’s really the purpose of that meeting.
Unidentified Analyst: Okay. I’ll leave it there. Thank you.
Jack Khattar: Thank you.
Operator: Thanks. Please standby for our next question. And our next question comes from Stacy with TD Cowen. Go ahead, Stacy.
Stacy Ku: Hey. Congratulations on the quarter and thanks so much for taking your questions. So we do have a few follow-ups. And just one more on Calgary that strong net pricing that we’re seeing in Q1. What’s driving that? Is it higher doses because more adult patients are being added? Is it price increase? Is it still kind of that pulling back the co-pay assistance program? And then as we look forward as we consider these kind of growth mix fluctuations that you kind of alluded to? Are you going to be making investments as we think about back-to-school season this year, just quarter-to-quarter or we just — or should we expect a more stable net price for the year? That’s the first question. And then the second question is going to be on SPN-817.
It sounds like enrollment went a bit faster than expectations. So can you just broadly talk about steady demand among the patients? And then just set expectations, what you expect will be competitive seizure reduction through forward understanding this is an open label and you’re going to give this data in late May, but just curious the decision to move into late May and help set expectations for the Street. Thank you.
Jack Khattar: Regarding Calgary and we’ve talked about that actually several quarters regarding what are the key drivers for Qelbree to continue to grow and to continue to really perform well and obviously continue to grow the net price at the end of the day. Clearly, higher daily doses and we can get there through different avenues. Highly daily doses that patients are taking on a daily basis, whether it’s pediatric or adult, and that is typically a function of physicians getting more and more comfortable with the medication and titrating up to the real dose that they need to use actually for the product to be very well, effective in treating symptoms. And that is in line with the Phase 3 data. And based on the Phase 3 data, we continue to communicate to our physicians, what are the target total daily dose that they should be working up to in both patient populations.
So, clearly, as time goes on, we are getting there. The speed by which we get there is always, you know, it’s hard to predict, obviously, because you always have new prescribers that are completely new to the product, and these new prescribers will always take it low and slow, so to speak, from a titration perspective. It also depends on how they’re using it. If they’re using it in combination with stimulants, sometimes they go much lower and much slower because they’re adding it to the stimulants that the patient is already on. And as they try to take the stimulant off from the therapeutic regimen for that patient, and adding Qelbree, they will reduce the stimulant and increase the Qelbree dose. So that’s a function of that patient on a case-by-case basis.
And then the final dynamic that will impact higher doses is clearly the adult population. You know, as our mix of the business continues to grow in adults and becomes a bigger piece of our total franchise on a blended basis clearly that’s going to increase the total daily dose and gives us the benefit of a higher price for a prescription. So the net price in the first quarter of this year was about 255 I guess, if you divide the net sales by the quarterly prescriptions, which is down versus 267, which was the number in the fourth quarter of last year. And that’s because the gross net always gets a little bit worse in the first quarter versus, the previous quarter. As far as the year goes on, our investments and so forth, now, at this moment, we continue to push in adults.
